Additional file 10 of Safety and efficiency of stem cell therapy for COVID-19: a systematic review and meta-analysis

Additional file 10. Ongoing Clinical Trials of Stem Cells Therapy for COVID-19. We searched clinical trials from the ClinicalTrials.gov database and the World Health Organization's International Clinical Trials Registry Platform (WHO ICTRP) and combined the data from the Global Coronavirus COVID-19 Clinical Trial Tracker ( https://covid19-trials.com/ ). Totally 177 studies were shown that related to stem cell and derivatives therapy for COVID-19 patients. The database search for this systematic review was conducted in March, 2022. The country with the most registered trials is the United States. Removing 9 registration numbers that we included, the recruitment status showed that there were 52 not yet recruiting, 7 authorized, 72 recruiting, 9 active, not recruiting and 16 completed but unpublished among the 168 registered clinical trials. The remaining 12 trials were suspended, terminated, withdrawn, available or of unknown status. Moreover, not all clinical trials that show completion have reported results. Based on these results, stem cell treatments for COVID-19 did not have sufficient completed Clinical trial data and were still in the experimental stage. Current published clinical trials had been collected in the systematic review and our evaluation implied that stem cell-based therapy might decrease mortality and improve clinical manifestation of patients diagnosed COVID-19.